Literature DB >> 18084320

A new fusion gene NUP98-IQCG identified in an acute T-lymphoid/myeloid leukemia with a t(3;11)(q29q13;p15)del(3)(q29) translocation.

Q Pan1, Y-J Zhu, B-W Gu, X Cai, X-T Bai, H-Y Yun, J Zhu, B Chen, L Weng, Z Chen, Y-Q Xue, S-J Chen.   

Abstract

NUP98 has been involved in multiple recurrent chromosome rearrangements in leukemia. We identified a novel fusion between NUP98 and IQ motif containing G (IQCG) gene from a de novo acute T-lymphoid/myeloid leukemia harboring t(3;11)(q29q13;p15)del(3)(q29). IQCG has two putative coiled-coil domains and one IQ domain. The FG repeat from NUP98 and the coiled-coil domain from IQCG were retained in the fusion protein. We demonstrated that NUP98-IQCG could form homodimer, heterodimerize with NUP98 or IQCG, bind co-activators and/or co-repressors, and show transcriptional activity in vitro. Expression of NUP98-IQCG inhibited 32Dcl3 cell apoptosis induced by Ara-C, and partially blocked granulocyte differentiation induced by G-CSF. Colony-forming assay and serial replating assays indicated that NUP98-IQCG was able to stimulate proliferation, partially block differentiation of hematopoietic stem/progenitor cells but was unable to confer transformation alone. Taken together, our data indicate that newly identified NUP98-IQCG fusion protein may play an essential role in leukemogenesis, but by itself may not be sufficient to induce leukemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18084320     DOI: 10.1038/sj.onc.1210999

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  Amino-terminal enhancer of split (AES) interacts with the oncoprotein NUP98-HOXA9 and enhances its transforming ability.

Authors:  Nayan J Sarma; Nabeel R Yaseen
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  Human NUP98-IQCG fusion protein induces acute myelomonocytic leukemia in mice by dysregulating the Hox/Pbx3 pathway.

Authors:  M M Pan; Q Y Zhang; Y Y Wang; P Liu; R B Ren; J Y Huang; L T Chen; X D Xi; Z Chen; S J Chen
Journal:  Leukemia       Date:  2015-12-17       Impact factor: 11.528

Review 3.  NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights.

Authors:  Sheryl M Gough; Christopher I Slape; Peter D Aplan
Journal:  Blood       Date:  2011-09-26       Impact factor: 22.113

4.  Functional analysis of the NUP98-CCDC28A fusion protein.

Authors:  Arnaud Petit; Christine Ragu; Gwendoline Soler; Chris Ottolenghi; Caroline Schluth; Isabelle Radford-Weiss; Sylvie Schneider-Maunoury; Isabelle Callebaut; Nicole Dastugue; Harry A Drabkin; Olivier A Bernard; Serge Romana; Virginie Penard-Lacronique
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

Review 5.  Sperm dysfunction and ciliopathy.

Authors:  Kazuo Inaba; Katsutoshi Mizuno
Journal:  Reprod Med Biol       Date:  2015-10-14

6.  Formation of Nup98-containing nuclear bodies in HeLa sublines is linked to genomic rearrangements affecting chromosome 11.

Authors:  Serge Romana; Isabelle Radford-Weiss; Jean-Michel Lapierre; Valérie Doye; Marie-Claude Geoffroy
Journal:  Chromosoma       Date:  2015-12-21       Impact factor: 4.316

7.  Inhibition of the nuclear export of p65 and IQCG in leukemogenesis by NUP98-IQCG.

Authors:  Mengmeng Pan; Qiyao Zhang; Ping Liu; Jinyan Huang; Yueying Wang; Saijuan Chen
Journal:  Front Med       Date:  2016-12-23       Impact factor: 4.592

8.  The role of Nup98 in transcription regulation in healthy and diseased cells.

Authors:  Tobias M Franks; Martin W Hetzer
Journal:  Trends Cell Biol       Date:  2012-12-13       Impact factor: 20.808

Review 9.  Nuclear pore proteins and cancer.

Authors:  Songli Xu; Maureen A Powers
Journal:  Semin Cell Dev Biol       Date:  2009-03-18       Impact factor: 7.727

Review 10.  Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies.

Authors:  Nicole L Michmerhuizen; Jeffery M Klco; Charles G Mullighan
Journal:  Blood       Date:  2020-11-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.